COMPANY
Gliknik
Timeline
- Trial start Phase 1: Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia source ↗
- Trial start Phase 1: Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With source ↗
- Trial start Phase 2: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity source ↗
Upcoming milestones
- Dec 6, 2027 (ESTIMATED) · Phase 1 · Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia · NCT07605845
Clinical trials (lead sponsor) 3
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07605845 | Safety and Efficacy of GL-2045 in Patients With Immune Thrombocytopenia | Phase 1 | Recruiting | Apr 14, 2026 | Dec 6, 2027 (estimated) |
| NCT05318534 | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects and Safety, Tolerability, Pharmacokinetics, and Pilot Efficacy Biomarkers in Subjects With Cold Agglutinin Disease | Phase 1 | Recruiting | Apr 8, 2022 | Jun 30, 2026 (estimated) |
| NCT02873819 | Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Completed | Mar 30, 2017 | May 17, 2021 (actual) |
NIH awards 2
- NIH contract (government contract; not a grant and not an investment round) 261201100103C-0-0-1 FY2011: $1,500,000 awarded for that fiscal year; activity N44 (OTHER_NIH); PI OLSEN, HENRIK; recipient as written: GLIKNIK, INC., BALTIMORE, MD. TAS::75 0849::TAS; source ↗
- NIH contract (government contract; not a grant and not an investment round) 261200900084C-0-0-1 FY2009: $150,000 awarded for that fiscal year; activity N43 (OTHER_NIH); PI OLSEN, HENRIK; recipient as written: GLIKNIK, INC., BALTIMORE, MD. BIOMEDICAL (BASIC) source ↗